Company: LAZ
Filing Date: 2025-09-08
Form Type: 8-K
Source: 0001311370-25-000041
Chunk: 0

Company: Lazard, Inc.
Filing Date: 2025-09-08
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Transition of Evan L. Russo

On September 8, 2025, Lazard, Inc. (the “ Company”) announced that Evan L. Russo will transition from his role as Chief Executive Officer of Lazard’s asset management business effective on or around December 1, 2025 (and no later than December 31, 2025) (the “ Transition Date”) into a non-executive officer role as Senior Advisor to the Chief Executive Officer of the Company (“ Senior Advisor”). Mr. Russo will continue employment with the Company as Senior Advisor through June 30, 2026 (such date the “ Separation Date”, and such period, the “ Advisory Period”). As of the Separation Date, Mr. Russo’s service with the Company will cease.

Transition Agreement with Mr. Russo

In connection with such transition, on September 7, 2025, the Company and Mr. Russo entered into a transition agreement (the “ Russo Transition Agreement”), pursuant to which (1) his service as Chief Executive Officer of Lazard’s asset management business will cease as of the Transition Date and (2) on the Transition Date, he will transition into the role of Senior Advisor and will continue employment in such role through the Separation Date.

As compensation for services performed during the Advisory Period, Mr. Russo will receive his base salary at its current rate, continue to participate in the Company’s benefit plans and programs in accordance with their terms and be eligible to vest in his outstanding equity-based awards in accordance with their terms.

As of the Separation Date, Mr. Russo will be eligible to receive (1) the severance benefits payable upon a qualifying termination (prior to a change in control) under his Amended and Restated Agreement Relating to Retention and Noncompetition and Other Covenants, dated as of March 31, 2022 and amended as of May 25, 2023, and the (2) treatment of outstanding equity-based awards in accordance with their terms, in each case subject to and in accordance with the terms of the applicable arrangement and as described (as applicable) in the Company’s Definitive Proxy Statement on Schedule 14A filed on March 25, 2025(the “2025 Proxy Statement”) under “ Potential Payments Upon Termination or Change in Control”, “ Individual Agreements” and “ Award Agreements -